Response rates in patients with acute myeloid leukemia (AML), treated with azacitidine, using WHO and international working group (IWG) criteria for myelodysplastic syndrome (MDS).

被引：11
|
作者：
Silverman, LR
McKenzie, DR
Peterson, BL
Stone, RM
Powell, BL
Mayo, C
Backstrom, JT
Larson, RA
机构：
[1] Mt Sinai Sch Med, New York, NY USA
[2] Pharm Corp, Overland Pk, KS USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA
[6] Univ Chicago, Chicago, IL 60637 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.1848.1848
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1848
引用
收藏
页码：525A / 526A
页数：2
相关论文
共 50 条
  • [1] Response rates using international working group (IWG) criteria in patients with myelodysplastic syndromes (MDS) treated with azacitidine.
    Silverman, LR
    McKenzie, DR
    Peterson, BL
    De Castro, CM
    Ellerton, J
    Knapp, KN
    Beach, CL
    Larson, RA
    BLOOD, 2005, 106 (11) : 709A - 709A
  • [2] Hospitalization rates in elderly, newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients treated with azacitidine.
    Ueda, Masumi
    Gupta, Divya
    Caimi, Paolo Fabrizio
    Creger, Richard
    Little, Jane
    William, Basem M.
    Lazarus, Hillard M.
    De Lima, Marcos J. G.
    Cooper, Brenda W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine
    Kuendgen, Andrea
    Mueller-Thomas, Catharina
    Urbaniak, Petra
    Lauseker, Michael
    Haferlach, Torsten
    Alpermann, Tamara
    Albuquerque, Andreia
    Kohlmann, Alexander
    Schnittger, Susanne
    Hildebrandt, Barbara
    Royer-Pokora, Brigitte
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    Goetze, Katharina
    BLOOD, 2013, 122 (21)
  • [4] BASOPHILIA IN PATIENTS WITH MYELODYSPLASIC SYNDROME (MDS)/ACUTE MYELOID LEUKEMIA (AML) WHO RESPOND TO TREATMENT WITH AZACITIDINE
    Calderon Lopez, M. T.
    Garcia Leon, N.
    Seri Merino, C.
    Sandoval Barreto, E.
    Otero Martinez, M. J.
    Matilla Garcia, A.
    HAEMATOLOGICA, 2019, 104 : 439 - 440
  • [5] Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Itzykson, Raphael
    Thepot, Sylvain
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    BLOOD, 2010, 116 (21) : 199 - 199
  • [6] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [7] Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
    Williams, Loretta A.
    Ault, Patricia S.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Faderl, Stefan H.
    Jabbour, Elias J.
    Cleeland, Charles S.
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [8] Analysis of mutations associated with response to glasdegib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Ching, Keith A.
    Huang, Donghui
    Wang, Kai
    Ozeck, Mark
    Lira, Paul
    Gao, Jingjin
    Bienkowska, Jadwiga
    Rejto, Paul
    Hardwick, James
    O'Brien, Thomas
    Chan, Geoffrey
    CANCER RESEARCH, 2018, 78 (13)
  • [9] Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine
    Shabanova, Iren
    Cada, Michaela
    Johnston, Donna L.
    Abbott, Lesleigh S.
    Leung, Elaine W.
    Schechter, Tal
    Dror, Yigal
    Klaassen, Robert J.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2020, 42 (03) : 170 - 174
  • [10] Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria
    Gattermann, Norbert
    Finelli, Carlo
    Della Porta, Matteo
    Fenaux, Pierre
    Stadler, Michael
    Guerci-Bresler, Agnes
    Schmid, Mathias
    Taylor, Kerry
    Vassilieff, Dominique
    Habr, Dany
    Marcellari, Andrea
    Roubert, Bernard
    Rose, Christian
    BLOOD, 2010, 116 (21) : 1199 - 1199
12345